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Abstract
Background: Sporadic non-clustered hospital-associated listeriosis is an emerging infectious disease in
immunocompromised hosts. The current study was designed to determine the impact of long-term and precipitating
immunosuppressive agents and underlying diseases on triggering the expression of the disease, and to compare the
clinical features and outcome of hospital-associated and community-associated listeriosis.
Methods: We reviewed the medical records of all patients with Listeria monocytogenes isolated from sterile body sites
at a large medical center in southern Taiwan during 1992–2013. Non-clustered cases were defined as those unrelated
to any other in time or place. Multivariable regression analysis was used to determine factors associated with prognosis.
Results: Thirty-five non-clustered cases of listeriosis were identified. Twelve (34.2%) were hospital-associated, and
23 (65.7%) were community-associated. The 60-day mortality was significantly greater in hospital-associated
than in community-associated cases (66.7% vs. 17.4%, p = 0.007). Significantly more hospital-associated than
community-associated cases were treated with a precipitating immunosuppressive agent within 4 weeks prior to
onset of listeriosis (91.7% vs. 4.3%, respectively p < 0.001). The median period from the start of precipitating
immunosuppressive treatment to the onset of listeriosis-related symptoms was 12 days (range, 4–27 days) in 11 of the
12 hospital-associated cases. In the multivariable analysis, APACHE II score >21 (p = 0.04) and receipt of precipitating
immunosuppressive therapy (p = 0.02) were independent risk factors for 60-day mortality.
Conclusions: Sporadic non-clustered hospital-associated listeriosis needs to be considered in the differential
diagnosis of sepsis in immunocompromised patients, particularly in those treated with new or increased doses
of immunosuppressive agents.
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Background
Listeria monocytogenes is an important cause of disease
in humans, particularly in patients with impaired cellular
immunity [1]. The common manifestations include lis-
teriosis during pregnancy, sepsis and meningitis in new-
borns, acute febrile gastroenteritis, invasive disease in
food-borne outbreaks, and fatal disseminated infection
in immunocompromised hosts [1,2]. Unusual localized
infections such as pneumonia, hepatitis, arthritis and en-
dophthalmitis have also been reported [2]. The clinical
presentation of non-perinatal listeriosis depends on pre-
disposing factors. Patients with a severe immunocom-
promised status tend to have bacteremia without a focus,
localized infection, and central nervous system (CNS) in-
fection with coma or encephalitis [1].
L. monocytogenes is a common colonizer of the human
gastrointestinal tract with the asymptomatic carrier rate
in the general population reported to be 1–10% [3]. The
occurrence of invasive listeriosis depends on the integ-
rity of the immune system of the host, and the number
of bacteria delivered to the intestinal tract [4,5]. After
entering a susceptible host, L. monocytogenes adheres to
the host receptor E-cadherin [6], is transcytosed across
the intestinal epithelium barrier, and then released
into the lamina propria by exocytosis [7]. Most of the
bacteria become trapped in the liver and spleen by mac-
rophages. In innate immunity, macrophages play an
important role in initial control of infection because rep-
lication of L. monocytogenes occurs primarily within the
macrophages that mediate clearance of bacteria. After
specific recognition of pathogen-derived products by
Toll-like receptors on macrophages, dendritic cells are
activated and initiate CD4 and CD8 T cell responses that
result in a stable population of L. monocytogenes-specific
memory T cells [8]. The microorganism can escape im-
mune clearance and re-enter the bloodstream to cause
potentially fatal disease unless their replication is con-
trolled by a functional host immune response. Precipitating
immunosuppressive agents may lead to the development
of invasive disease from latent or subclinical infection.
Listeriosis is mainly transmitted through consumption
of contaminated food in the community [9], and ver-
tical transmission from mother to child [10]. Hospital-
associated infections usually occur as clustered outbreaks
from environmental contact [11-17] or contaminated food
[18-25]. Sporadic non-clustered hospital-associated listeri-
osis is an emerging infectious disease. It has been reported
in many countries including the United States [26,27],
Europe [1,28,29], Australia [30], Israel [2] and more re-
cently China [31]. It may be triggered from latent or sub-
clinical infection by immunosuppressive agents, but the
exact pathogenesis and source still needs to be identified.
In view of the relatively high rate of asymptomatic carriers
of L. monocytogenes in the general population [3] and the
increasing numbers of patients receiving potent immuno-
suppressive agents, listeriosis needs to be considered in
the differential diagnosis of sepsis in immunocomprom-
ised patients.
The current retrospective study of cases at a large
teaching medical center in southern Taiwan during a
21-year period was designed to better understand the
impact of immunosuppressive agents and underlying
diseases in triggering listeriosis, and to compare the clin-




This retrospective study examined the medical records
of patients with listeriosis over a 21-year period from
January 1992 to February 2013 at Kaohsiung Veterans
General Hospital, a 1200-bed general and tertiary care
hospital located in southern Taiwan. We reviewed the
data of all patients from whom L. monocytogenes was
isolated from blood and other sterile sites, including
CSF, ascites, pleural effusion and joint fluid. The iden-
tified cases were divided into community-associated
or hospital-associated infections according to the defi-
nitions detailed below. The two groups were then com-
pared according to demographic characteristics, underlying
diseases, clinical manifestations, laboratory findings, use of
immunosuppressive agents, and outcomes. The clinical
manifestations and laboratory findings, including APACHE
II score, used in the analysis were recorded at the onset of
symptoms that were compatible with listeriosis. The study
was approved by the ethics committees in Kaohsiung
Veterans General Hospital (VGHKS13-CT11-06).
Definitions
Listeriosis was indicated when L. monocytogenes was iso-
lated from sterile body sites including blood, cerebro-
spinal or joint fluid of patients with a compatible illness.
Hospital-associated cases were patients whose symp-
toms developed ≥48 hours after admission or within
14 days after discharge for another medical condition.
Community-associated cases were patients who pre-
sented with signs or symptoms compatible with lis-
teriosis <48 hours after admission. Non-clustered cases
were patients unrelated to any other in time or place.
Long-term immunosuppressive therapy was receipt of the
same immunosuppressive agent for management of an
underlying disease for >4 weeks before the development
of symptoms related to listeriosis. Precipitating immuno-
suppressive therapy was receipt of a new immunosuppres-
sive agent or intensified immunosuppressive treatment for
the management of disease flare-ups within 4 weeks prior
to development of symptoms compatible with listeriosis.
CNS infections were meningitis or brain abscesses with
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abnormal findings on lumbar punctures, but not necessar-
ily with a positive cerebrospinal fluid (CSF) culture. For
cases without a positive CSF culture, the diagnosis of CNS
infection was based on a positive blood culture with com-
patible CSF or imaging findings. Listeriosis-related symp-
toms included fever, reduced consciousness, headache,
seizure or nausea, which had no alternative cause. Ad-
equate antibiotic therapy was treatment with penicillin,
ampicillin or vancomycin within 24 hours after onset of
symptoms related to listeriosis. Mortality was all-cause
death within 60 days after the onset of symptoms compat-
ible with listeriosis.
Statistical analysis
The statistical analyses were performed using SPSS ver-
sion 12.0 (SPSS Inc., Chicago, IL, USA). Categorical vari-
ables were compared using the χ2 or Fisher’s exact tests,
and non-categorical variables were compared using the
Mann–Whitney U test. All tests were two-tailed, and
p < 0.05 was considered significant. Univariable and
multivariable analyses of prognostic factors were per-
formed using the LOGISTIC procedure. For the mul-
tivariable analysis of mortality, candidate variables were
identified as those having a univariate significance of
p ≤ 0.10, those identified in a previous study, or those
believed to be clinically meaningful.
Results
Demographic characteristics and underlying diseases of
listeriosis patients
Thirty-five cases were identified during the 21-year
study period (Table 1). All were adults and non-
clustered cases (Figure 1). The median age was 61 years
(range 20–87 years) and 18 (51.4%) were male. Twelve
cases (34.2%) had hospital-associated and 23 (65.7%)
had community-associated listeriosis. There were no
significant differences in age, sex, or underlying disease
between community-associated and hospital-associated
cases.
Immunocompromised status of listeriosis patients
Thirty-two of the 35 (91.4%) patients were immunocom-
promised. Many of these patients had several diseases
associated with immune deficiency (Table 1). These in-
cluded neoplastic, autoimmune and steroid-dependent ob-
structive pulmonary diseases, alone or in combination
with other diseases such as diabetes, chronic renal failure,
and hepatic cirrhosis. No patients had HIV infection or
organ transplantation. Eighteen patients (51.4%) received
one or more immunosuppressive agents (Table 1). Eight
(44.4%) of these 18 patients received long-term immuno-
suppressive agents, 12 (66.7%) received a precipitating im-
munosuppressive agent, and two (11.1%) received both
long-term and precipitating immunosuppressive agents.
Of those receiving a precipitating immunosuppressive
agent, six (50%) patients received a corticosteroid and six
(50%) received both a corticosteroid and chemotherapy.
Hospital-associated cases were significantly more likely
than community-associated cases to have received a pre-
cipitating immunosuppressive agent (n = 11, 91.7% vs.
n = 1, 4.3%, p < 0.01).
Clinical and laboratory manifestations of listeriosis
The clinical and laboratory findings of the 35 cases
of listeriosis are summarized in Table 2 and Figure 2.
L. monocytogenes was isolated from blood cultures in
Table 1 Demographic characteristics and underlying diseases among 35 cases of listeriosis [1]
All (n = 35) Community-associated (n= 23) Hospital-associated (n= 12) p-value
Age, median years (range) 61 (20–87) 64 (29–87) 68 (21–81) 0.29
Male sex (%) 18 (51.4) 11 (47.8) 7 (58.3) 0.56
Diabetes mellitus (%) 10 (28.6) 8 (34.8) 2 (16.7) 0.43
Chronic kidney disease (%) 12 (34.3) 10 (43.4) 2 (16.7) 0.15
Hematologic malignancy (%) 5 (14.3) 2 (8.6) 3 (25.0) 0.31
Solid tumor (%) 12 (28.6) 4 (17.4) 6 (50) 0.06
Autoimmune disease (%) 8 (22.9) 6 (26.1) 2 (16.7) 0.69
Immunosuppressive agents (%) 18 (51.4) 7 (30.4) 11 (91.7) < 0.01
Long-term immunosuppressive agentsa (%) 8 (22.9) 7 (30.4) 1 (8.3) 0.22
Precipitating immunosuppressive agentsb (%) 12 (34.3) 1 (4.3) 11 (91.7) < 0.01
Chronic obstructive pulmonary disease (%) 3 (8.6) 1 (4.3) 2 (16.7) 0.27
Liver cirrhosis (%) 6 (17.1) 5 (21.7) 1 (8.3) 0.64
Peptic ulcer disease (%) [32] 7 (20) 7 (30.4) 0 0.07
Data are no. (%) of patients, unless otherwise indicated.
aThese included corticosteroids alone in 5; corticosteroids plus a biological agent in 1; and corticosteroids plus azathioprine in 2.
bThese included high doses of corticosteroids and chemotherapy.
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33 of the 35 (94.2%) patients. The other two cases with
negative blood cultures had L. monocytogenes isolated
from joint fluid or from CSF. Among the 10 patients
with CNS involvement, the organism was isolated from
the initial CSF in six (60%) and from blood in nine (90%).
Most of the 35 patients were febrile (88.6%) and 37.1%
had symptoms of CNS involvement. These included
altered consciousness, seizure and focal neurological
findings. There were no other significant differences be-
tween the groups in clinical or laboratory findings.
The clinical presentation of the 35 cases of listeriosis is
shown in Figure 2. The most common clinical syndrome
was primary bacteremia in 20 (57%) patients. Ten (28%) pa-
tients had CNS involvement, seven with meningitis and
three with a brain abscess. Localized infection presenting as
septic arthritis of the knee was noted in one case (2.9%).
Figure 1 Distribution of 35 cases of listeriosis by calendar year over a period of 21 years.
Table 2 Clinical manifestations, laboratory findings and outcomes among 35 cases of listeriosis
All (n = 35) Community-associated (n = 23) Hospital-associated (n = 12) p-value
Clinical findings
APACHE II score, median (range) 15 (4–46) 12 (4–46) 19 (6–30) 0.55
Headache (%) 4 (11.4) 3 (13) 1 (8.3) 1.0
Nausea (%) 3 (8.6) 1 (4.3) 2 (16.7) 0.27
Reduced consciousness (%) 11 (31.4) 6 (26.1) 5 (41.7) 0.45
Seizure (%) 6 (17.1) 3 (13) 3 (25) 0.39
Focal neurologic (%) 3 (8.6) 2 (8.7) 1 (8.3) 1.0
Diarrhea (%) 3 (8.6) 2 (8.7) 1 (8.3) 1.0
Fever (%) 31 (88.6) 20 (87) 11 (91.7) 1.0
Adequate antibiotic therapy within 24 hours (%) 4 (11.4) 1 (4.3) 3 (25) 0.16
CNS infection (%) 10 (28.6) 8 (34.8) 2 (16.7) 0.43
60-day mortality (%) 12 (34.3) 4 (17.4) 8 (66.7) 0.01
Hospital duration, median day (range) 28 (1–126) 20 (1–124) 53 (15–126) 0.01
Laboratory findings
ALT, median IU/L (range) 41 (6–248) 47.5 (6–248) 39 (15–177) 0.88
Total bilirubin, median mg/dL (range) 0.9 (0.2–7.9) 0.8 (0.2–4) 0.5 (0.2–7.9) 0.24
Albumin, median g/dL (range) 2.7 (1.4–3.9) 2.6 (1.7–3.8) 2.4 (1.4–3.9) 0.93
White blood cells, median 109/L (range) 8.38 (0.19–28.16) 13.39 (3.36–27.47) 8.38 (0.19–28.16) 0.06
Platelets, median /mm3 (range) 117 (4–350) 158.72 (27.7–350) 101.91 (4–275) 0.18
Serum creatinine, median mg/dL (range) 1.1 (0.4–17.2) 1.10 (0.58–17.2) 1.10 (0.4–8.84) 0.07
Site of L. monocytogenes isolates
Blood (%) 33 (94.3) 21 (91.3) 12 (100) 0.54
CSF (%) 6 (17.1) 5 (21.7) 1 (8.3) 0.64
Joint fluid (%) 1 (2.8) 1 (4.3) 0 (0) 1.0
Data are no. (%) of patients, unless otherwise indicated. APACHE II, Acute Physiology And Chronic Health Evaluation II; ALT, alanine aminotransferase.
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Outcomes
Twelve of the 35 patients (34.2%) died, all as a direct re-
sult of listeriosis. Hospital-associated cases had a longer
hospital stay (53 vs. 20 days, p = 0.01) and a greater 60-day
mortality rate (66.7 vs. 17.4%, p = 0.01) than community-
associated cases (Table 2). In multivariable analysis of
60-day mortality, an APACHE II score > 21 [odds ratio
(OR), 40.43; 95% confidence interval (CI), 1.07-1515.00;
p = 0.04] and receipt of a precipitating immunosuppres-
sive agent within 4 weeks (OR, 285.81; 95% CI, 2.34–
34859.49; p = 0.02) were prognostic indicators of poor
survival (Table 3). Four of the 35 (11.4%) cases were
treated with an appropriate antibiotic within 24 hours
following the onset of the listeriosis-related symptoms.
Two were treated with penicillin for suspected pneumo-
nia; one with ampicillin and gentamicin for lymphocytic
meningitis; and one patient received vancomycin for sus-
pected recurrence of methicillin-resistant Staphylococcus
aureus bacteremia.
Clinical characteristics and precipitating immunosuppressive
agents in 12 sporadic non-clustered cases of
hospital-associated listeriosis
Detailed information about the underlying diseases, cause
of admission, clinical syndromes of listeriosis, and reason
for precipitating immunosuppressive therapy for the 12
hospital-associated cases of listeriosis are shown in Table 4.
None of these cases showed clustering according to time
or place (Figure 1). Listeriosis-related symptoms ap-
peared at a median of 24 days (range, 10–59 days)
following admission. Ten (83.3%) of the patients had
primary bacteremia and two (16.7%) had meningitis with
bacteremia. Eleven of the 12 (91.7%) patients had re-
ceived a precipitating immunosuppressive agent within
4 weeks prior to the onset of listeriosis. Five of the 11
(45.4%) patients received corticosteroids at an equivalent
dose of prednisolone ≥1 mg/kg, and six (54.5%) patients
received both corticosteroids and chemotherapy. The
median time from the physician’s order for a precipitat-
ing immunosuppressive agent to the onset of listeriosis-
related symptoms was 12 days (range, 4–27 days). One of
the patients who did not receive a precipitating im-
munosuppressive agent had a severe underlying disease.
This was a left adrenal gland tumor with invasion of
the tail of the pancreas and multiple bone metastasis. It
is possible that the tumor may have damaged the integ-
rity of his gastrointestinal tract, leading to invasion with
L. monocytogenes.
Discussion
Sporadic, non-clustered, hospital-associated listeriosis is
a relatively rare, but life-threatening disease. We identi-
fied 12 cases in adults at a large medical center in south-
ern Taiwan over a period of 21 years, or 0.34 cases per
year. In a similar study conducted at a large tertiary care
hospital in China, Yang et al. found nine non-clustered
hospital-associated cases over a period of 12 years, or 0.75
cases per year [31]. We also identified 23 community-
associated cases. In the present study, 32 of the 35 cases
(91.4%) were immunocompromised. This is similar to pre-
vious reports [1,28,30,33]. The listeriosis-related mortality
rate of 34.3% observed in the current study is similar to
other reports (24–52%) [2]. The 60-day mortality rate was
significantly higher in patients with hospital-associated
than community-associated listeriosis (66.7% vs. 17.4%,
p = 0.007). Other reports showed a mortality rate of
hospital-associated listeriosis of 27.2–53% [30,31].
Table 3 Multivariable analysis of 60-day mortality in the






Age 0.94 0.847–1.049 0.28
Sex (male) 7.26 0.118–446.821 0.35
Chronic kidney disease 1.79 0.068–46.805 0.73
Autoimmune disease 0.18 0.001–21.830 0.48
Precipitating immunosuppressive
agentsa
285.82 2.343–34 859.494 0.02
CNS involvement 15.01 0.166–1362.565 0.24
APACHE II >21 40.44 1.079–1515.001 0.04
ALT 1.03 0.998–1.059 0.06










Septic arthritis Infectious diarrhea+bacteremia
Figure 2 Clinical syndromes of the 35 cases of listeriosis. The
majority (n = 20, 57%) presented as primary bacteremia without
obvious site of involvement. Central nervous system involvement
(n = 10, 28.6%) was the next most common. Other clinical
syndromes included infective endocarditis (n = 2, 6%), infectious
diarrhea (n = 2, 6%), and septic arthritis (n = 1, 3%).
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Although it may be argued that a hospital-associated
case defined by symptoms developing ≥48 hours after
admission could be a case of community-associated lis-
teriosis with a protracted course and delayed diagnosis,
detailed analysis of the cause of admission and initi-
ation of a precipitating immunosuppressive agent in
these 12 hospital-associated cases suggests these were
truly hospital-associated cases rather than community-
associated with a subacute course.
Reactivation of latent or subclinical infection by im-
munosuppressive agents provides an attractive explan-
ation for the mechanism of sporadic non-clustered
hospital-associated listeriosis in immunocompromised
hosts. In the present study, almost all of the non-clustered
Table 4 Clinical characteristics and detailed history of precipitating immunosuppressive agents in 12 sporadic
non-clustered cases of hospital-associated listeriosis





D 2b Cause of precipitating
immunosuppressive
agent
1 Breast cancer with liver
and lung metastasis









14 Primary bacteremia Corticosteroid 7 Management of paraplegia

























23 Pulse therapy for
lymphocytic myocarditis
5 New diagnosis of
pancreatic cancer
with lung metastasis
Evaluation of lung mass 30 Primary bacteremia Corticosteroid and
chemotherapy with
cyclophosphamide
22 For suspected Wegner’s
granuloma







42 Primary bacteremia Nil Nil
7 Lung cancer Management of
obstructive pneumonia
18 Primary bacteremia Corticosteroid 4 Management of paraplegia
caused by lung cancer
with spine metastasis


















caused by fluid overload




10 New diagnosis of
multiple myeloma























aDuration 1: from admission to onset of symptoms related to listeriosis (days).
bDuration 2: from prescription of precipitating immunosuppressive agent to onset of symptoms related to listeriosis (days).
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hospital-associated cases (n = 11, 91.7%) received a new or
more intensive precipitating immunosuppressive agent
within 4 weeks prior to the onset of listeriosis compared
with only 4.3% (n = 1) of the community-associated cases
(p < 0.001). Other investigators have reported the occur-
rence of listeriosis within 4 weeks after receiving chemo-
therapy or corticosteroids in patients with underlying
malignancies [2,33]. Listeriosis has also been reported
among patients undergoing therapy with biological agents
such as infliximab [26,27,29] and etanercept [34]. This
concept that immunosuppressive agents trigger latent lis-
teriosis is further supported by the relatively short time
interval (median 12 days; range, 4–27 days) from the
order for a precipitating immunosuppressive agent to onset
of severe, life-threatening hospital-associated listeriosis.
In the current study, only four of the 35 (11.4%) cases
were treated with an appropriate antibiotic within 24 hours
after the onset of listeriosis. The rate was low for both
community-associated and hospital-associated cases (4.3%
and 25%, p = 0.16). This may arise because of the non-
specific manifestations and rare occurrence of listeriosis,
combined with the primary physician being unfamiliar with
the disease. Education of physicians about the presentation
of listeriosis, especially sepsis and meningitis in the elderly
and immunocompromised patients, and in the setting
of new or increased treatment with immunosuppressive
agents in hospital may improve the rate of appropriate pre-
scribing of antimicrobial agents.
Mortality rates from listeriosis tend to be higher in se-
verely immunocompromised patients, such as those with
AIDS, or who receive immunosuppressive therapy for
organ transplantation, than in less immunocompromised
patients or apparently healthy hosts [1]. In the multivari-
able analysis of mortality we found that an APACHE II
score > 21 and receipt of precipitating immunosuppressive
agents within 4 weeks prior to the onset of listeriosis were
indicators of poor prognosis. Other factors reported in the
literature for poor prognosis include hepatic decompensa-
tion [33], renal failure, and age >65 years [35].
Prophylaxis with trimethoprim-sulfamethoxazole (TMP-
SMZ) for Pneumocystis jiroveci and Toxoplasma gondii is
given in patients with advanced human immunodeficiency
virus (HIV) infection and organ transplant recipients
[36-38]. In the current study, no patients had HIV infec-
tion or organ transplantation and they didn’t receive
TMP-SMZ prophylaxis at the onset of listeriosis. Mark
et al. revealed that prescription of TMP-SMZ for Pneumo-
cystis jiroveci prophylaxis in persons with HIV infection
also significantly decrease risk for other infections, includ-
ing Haemophilus, Salmonella, and S. aureus disease, but
not listeriosis [39]. However, estimation of TMP-SMZ
prophylaxis for listeriosis in HIV-infected patient and
other hosts with a severe immunocompromised status
needs further studies.
The strengths of the current study are the relatively
large number of cases of a rare disease and our ability to
determine the key role of precipitating immunosuppres-
sive agents as the major risk factor for life-threatening
sporadic non-clustered hospital-associated listeriosis. The
current study was conducted in a single institution in
Taiwan, but the findings are consistent with reports from
many other countries. The weakness is the retrospective
nature of this long-term study. However, this approach
was the only way we could collect a sufficient number of
cases for detailed analysis. It prevented us from being able
to identify the potential source(s) of infection, detect car-
riers, preserve the bacterial isolates for molecular epi-
demiological studies and to evaluate the efficacy of
antimicrobial therapy. Listeriosis is not a notifiable disease
in Taiwan. Therefore relevant data about the epidemiology
and clinical manifestations are limited [33,40-43].
Conclusions
Sporadic non-clustered hospital-associated listeriosis is
an emerging infectious disease in immunocompromised
hosts. It should be included in the differential diagnosis
of sepsis, particularly in those receiving new or increased
doses of immunosuppressive agents, such as corticoste-
roids or chemotherapy within the previous 4 weeks.
Whether the incidence of this disease will increase in as-
sociation with the development and widespread use of
new and more focused immunosuppressive agents needs
further study.
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